Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:GKOSNASDAQ:LMATNASDAQ:NARINYSE:STVN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGKOSGlaukos$103.50-0.1%$95.84$77.10▼$163.71$5.91B0.82739,359 shs289,937 shsLMATLeMaitre Vascular$84.41+0.7%$83.18$71.42▼$109.58$1.91B0.82169,905 shs75,102 shsNARIInari Medical$79.97$79.97$39.76▼$79.99$4.68B1.021.43 million shsN/ASTVNStevanato Group€24.59+0.4%€23.32€17.12▼€25.88€7.45B0.55322,736 shs190,500 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGKOSGlaukos-0.17%+2.25%+9.45%+23.77%-13.12%LMATLeMaitre Vascular+0.67%+2.44%+1.87%+5.80%+3.83%NARIInari Medical0.00%0.00%0.00%0.00%+59.91%STVNStevanato Group+0.29%-2.58%+12.59%+29.35%+36.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGKOSGlaukos4.4512 of 5 stars4.41.00.04.42.71.70.6LMATLeMaitre Vascular2.7158 of 5 stars2.21.03.30.02.62.51.3NARIInari MedicalN/AN/AN/AN/AN/AN/AN/AN/ASTVNStevanato Group1.2594 of 5 stars0.02.00.80.02.70.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGKOSGlaukos 2.75Moderate Buy$134.6730.11% UpsideLMATLeMaitre Vascular 2.33Hold$97.8315.90% UpsideNARIInari Medical 2.14Hold$69.22-13.44% DownsideSTVNStevanato Group 2.86Moderate BuyN/AN/ACurrent Analyst Ratings BreakdownLatest LMAT, STVN, GKOS, and NARI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025STVNStevanato GroupWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/6/2025GKOSGlaukosMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$110.00 ➝ $72.005/2/2025GKOSGlaukosStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$140.00 ➝ $115.005/1/2025GKOSGlaukosTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$140.00 ➝ $135.005/1/2025GKOSGlaukosStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$140.00 ➝ $115.005/1/2025GKOSGlaukosNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$176.00 ➝ $115.005/1/2025GKOSGlaukosWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$160.00 ➝ $86.004/21/2025STVNStevanato GroupStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/16/2025GKOSGlaukosMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$200.00 ➝ $175.004/15/2025GKOSGlaukosPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$180.00 ➝ $165.004/11/2025GKOSGlaukosTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$185.00 ➝ $140.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGKOSGlaukos$383.48M15.42N/AN/A$13.91 per share7.44LMATLeMaitre Vascular$219.86M8.67$2.39 per share35.33$15.00 per share5.63NARIInari Medical$493.63M9.48$0.09 per share906.95$8.07 per share9.91STVNStevanato Group€1.19B6.23€0.75 per share32.58€5.02 per share4.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGKOSGlaukos-$146.37M-$2.37N/AN/AN/A-31.40%-10.66%-8.06%7/30/2025 (Estimated)LMATLeMaitre Vascular$44.04M$1.9842.6338.902.2319.96%13.53%9.78%7/30/2025 (Estimated)NARIInari Medical-$1.64M-$1.35N/A727.00N/A-13.68%-10.09%-6.60%N/ASTVNStevanato Group€127.45M€0.5148.2242.402.3511.14%10.00%6.03%N/ALatest LMAT, STVN, GKOS, and NARI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025GKOSGlaukos-$0.26N/AN/AN/A$115.49 millionN/A5/1/2025Q1 2025LMATLeMaitre Vascular$0.50$0.48-$0.02$0.48$57.61 million$59.87 million4/30/2025Q1 2025GKOSGlaukos-$0.33-$0.22+$0.11-$0.32$102.78 million$106.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGKOSGlaukosN/AN/AN/AN/AN/ALMATLeMaitre Vascular$0.800.95%N/A40.40%14 YearsNARIInari MedicalN/AN/AN/AN/AN/ASTVNStevanato GroupN/AN/AN/AN/A1 YearsLatest LMAT, STVN, GKOS, and NARI DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025STVNStevanato Groupannual€0.060.3%6/5/20256/5/20257/17/20254/29/2025LMATLeMaitre Vascularquarterly$0.201%5/15/20255/15/20255/29/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGKOSGlaukos0.096.495.62LMATLeMaitre Vascular0.4816.4913.83NARIInari MedicalN/A1.771.40STVNStevanato Group0.221.831.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGKOSGlaukos99.04%LMATLeMaitre Vascular84.64%NARIInari Medical90.98%STVNStevanato GroupN/AInsider OwnershipCompanyInsider OwnershipGKOSGlaukos5.80%LMATLeMaitre Vascular9.50%NARIInari Medical10.60%STVNStevanato Group0.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGKOSGlaukos78057.14 million53.83 millionOptionableLMATLeMaitre Vascular49022.59 million20.45 millionOptionableNARIInari Medical80058.54 million52.34 millionOptionableSTVNStevanato Group5,521302.84 million300.72 millionOptionableLMAT, STVN, GKOS, and NARI HeadlinesRecent News About These CompaniesPalisade Capital Management LP Acquires 31,283 Shares of Stevanato Group S.p.A. (NYSE:STVN)July 4 at 6:05 AM | marketbeat.comBessemer Group Inc. Acquires 13,161 Shares of Stevanato Group S.p.A. (NYSE:STVN)July 3 at 3:51 AM | marketbeat.comStevanato Group (NYSE:STVN) Receives "Outperform" Rating from William BlairJuly 1 at 2:35 AM | americanbankingnews.comStevanato Group S.p.A. (NYSE:STVN) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 1 at 2:22 AM | marketbeat.comWilliam Blair Reaffirms Outperform Rating for Stevanato Group (NYSE:STVN)June 30, 2025 | marketbeat.comStevanato Group S.p.A. (NYSE:STVN) Shares Bought by Peregrine Capital Management LLCJune 30, 2025 | marketbeat.comSTVN Stevanato Group S.p.A. - Seeking AlphaJune 29, 2025 | seekingalpha.comStevanato Group (NYSE:STVN) Sets New 1-Year High - What's Next?June 26, 2025 | marketbeat.comStevanato Group S.P.A. (IT0005452658.SG)June 26, 2025 | sg.finance.yahoo.comCooper Investors PTY Ltd. Buys 25,221 Shares of Stevanato Group S.p.A. (NYSE:STVN)June 24, 2025 | marketbeat.comStevanato: Recovery Underway, Buy ConfirmedJune 22, 2025 | seekingalpha.comStevanato Group S.p.A. (NYSE:STVN) Shares Sold by Riverbridge Partners LLCJune 20, 2025 | marketbeat.comUSNA vs. STVN: Which Stock Is the Better Value Option?June 18, 2025 | zacks.comConestoga Capital Advisors LLC Raises Position in Stevanato Group S.p.A. (NYSE:STVN)June 17, 2025 | marketbeat.comStevanato Group (NYSE:STVN) Shares Down 4.7% - Here's What HappenedJune 12, 2025 | marketbeat.comSubcontractor sues for nearly $1.6M in unpaid work on Stevanato site in FishersJune 12, 2025 | theindianalawyer.comTYarbrough Capital LLC Acquires Shares of 16,113 Stevanato Group S.p.A. (NYSE:STVN)June 8, 2025 | marketbeat.comStevanato Group S.p.A. (NYSE:STVN) Receives Average Recommendation of "Moderate Buy" from AnalystsJune 6, 2025 | marketbeat.comStevanato Group S.p.A. (NYSE:STVN) Short Interest UpdateJune 5, 2025 | marketbeat.comEx-Dividend Reminder: Stevanato Group SpA, Golden Ocean Group and Flowers FoodsJune 4, 2025 | nasdaq.comWellington Management Group LLP Trims Position in Stevanato Group S.p.A. (NYSE:STVN)June 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLMAT, STVN, GKOS, and NARI Company DescriptionsGlaukos NYSE:GKOS$103.50 -0.13 (-0.13%) Closing price 07/3/2025 03:30 PM EasternExtended Trading$103.42 -0.08 (-0.07%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.LeMaitre Vascular NASDAQ:LMAT$84.41 +0.56 (+0.67%) Closing price 07/3/2025 01:44 PM EasternExtended Trading$84.41 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.Inari Medical NASDAQ:NARI$79.97 0.00 (0.00%) As of 02/19/2025Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.Stevanato Group NYSE:STVN€24.59 +0.11 (+0.45%) As of 07/3/2025 03:30 PM EasternStevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
